Natriuretic peptides and the reninangiotensin-aldosterone system (RAAS) have reciprocal effects at multiple sites and in varied situations. They interact in health and cardiovascular disease to influence renal, endocrine, and haemodynamic function and cardiovascular cell growth. The atrial natriuretic peptide (atrial natriuretic factor, ANF) discovered by De Bold in 19811 was cloned and sequenced by molecular biological techniques in 1984.2 The related peptides, brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP), were sequenced in 1988 and 1990, respectively. 34 The mature forms of the peptides share a common core structure consisting of a 17-amino acid ring with some conservation of amino acid residues between peptides ( fig  1) . 24 ANF is present at high concentrations in atrial tissue, and in lesser amounts in the central nervous system and plasma. BNP was originally identified in the porcine brain, but subsequent work showed that it is primarily a cardiac hormone. CNP, the most recently discovered member of the natriuretic peptide family, has no carboxy terminal extension ( fig  1) . It is widespread in vascular endothelium and is the most prevalent of the three peptides within the central nervous system, while little is present in the heart.
The natriuretic peptides exert their biological activity through specific cell receptors. Three natriuretic peptide receptors (NPR) have been characterised. NPR-A and NPR-B have guanylate cyclase activity and mediate biological activity through the second messenger cyclic guanosine monophosphate (cGMP). NPR-C is not guanylate cyclase linked, and functions as a "clearance receptor", removing natriuretic peptides from the circulation.5 ANF and BNP stimulate cGMP production through the NPR-A receptor. The NPR-B receptor is selective for CNP.6 The NPR-C (clearance receptor) binds all three of the natriuretic peptides. Natriuretic peptides are also subject to clearance by enzymatic degradation. The neutral endopeptidase EC 3A4'24'11 contributes to ANF clearance (and to a lesser extent BNP clearance) in humans. 7 The biochemistry of natriuretic peptides is further detailed in a recent review. 8 The focus of the present review is the interaction of the cardiac natriuretic peptides with the RAAS. Studies in humans will be reviewed, with additional information from in vitro or intact animal experiments where appropriate.
Reciprocal responses of natriuretic peptides and RAAS Secretion of ANF from the atria and BNP from cardiac ventricles is regulated by atrial distension and intraventricular pressures, respectively. The RAAS is activated with contraction of plasma volume and fall in renal perfusion. Renin secretion is stimulated through effects on the afferent arterial baroreceptor system, shifts in the filtered load of sodium presented to the macula densa, and by changes in renal sympathetic traffic. Renin stimulates production of circulating angiotensin II, a major secretagogue for aldosterone. The natriuretic peptides enhance natriuresis, lower blood pressure, and promote a contraction of plasma volume by shifting fluid volume from the intravascular to the extravascular space.9 In contrast, the RAAS promotes maintenance of circulating volume and arterial pressure through both renal sodium reabsorption and vasoconstrictor effects.
In view of these differing stimuli for secretion and opposed end organ biological effects, it is not surprising that plasma natriuretic peptide concentrations and circulating RAAS activity alter in reciprocal fashion in the face of a variety of physiological and experimental stimuli. For example, intravenous saline challenge increases plasma concentrations of ANF (although not BNP) while suppressing the RAAS.'0 Similarly, administration of diuretics, or conversely, expansion of central blood volume by means of lower body immersion, produces clear reciprocal changes in natriuretic peptide and RAAS activity." Dietary changes leading to shifts in cumulative sodium balance induce a direct parallel shift in plasma natriuretic peptides but a reciprocal change in renin.10 These observations do not allow distinction between the possibilities of independent reciprocal responses of natriuretic peptides and the RAAS to a given stimulus and potential direct effects of one circulating factor on the other.
Natriuretic peptide infusions in normal man
Administration of high doses of ANF, with associated substantial falls in arterial pressure, has no effect on plasma renin activity.'2 13 During an early experiment in which high doses of ANF caused a pronounced fall in blood pressure, plasma renin activity increased while aldosterone secretion was suppressed.'3 Therefore, in addition to any effect of ANF on aldosterone through the renin-angiotensin system, there is also a direct inhibitory effect of natriuretic peptides on the adrenal zona glomerulosa. Physiological doses of ANF consistently suppress both plasma renin activity and aldosterone concentrations. 9 group.bmj.com on October 15, 2017 -Published by http://heart.bmj.com/ Downloaded from CNP infused in normal men19 at a dose of 5 pmol/kg/min over a period of 2 h in placebo controlled studies increased plasma immunoreactive CNP levels to 60 pmol/l. Plasma ANF rose (approximately 2 pmol/l), as did plasma cGMP (approximately 1 nmol/l). Aldosterone concentrations fell, whereas plasma angiotensin II levels were not altered. CNP had no significant effect on the aldosterone or pressor responses to angiotensin II infusions. The observed effects on aldosterone and plasma cGMP may have been due to competitive displacement by CNP of ANF in common degradative pathways. In view of the likely role of CNP as a paracrine rather than endocrine hormone, the physiological or pathophysiological significance of these findings is uncertain.
The mechanisms underlying natriuretic peptide inhibition of renin secretion are not fully defined."5 Peptide-induced dilatation of the afferent glomerular arteriole may stimulate baroreceptors involved in the control of renin release from the juxtaglomerular apparatus. Enhanced delivery of sodium to the macula densa induced by natriuretic peptides will also inhibit renin release. The possibility that natriuretic peptides also act directly on juxtaglomerular cells to inhibit renin release has been addressed by in vitro experiments, but the data are conflicting.
Natriuretic peptides and angiotensin II bioactivity Natriuretic peptides oppose most of the known biological effects of angiotensin II. They antagonise angiotensin II induced aldosterone production. '8 20 Natriuretic peptide induced natriuresis is partly due to antagonism of the effects of angiotensin II on glomerular permeability and proximal tubular sodium reabsorption, as well as aldosterone secretion into the distal nephron.5 21 22 Recently, Garcia and Garvin23 have published evidence suggesting that the two peptides interact in the proximal straight tubule of the nephron through a mechanism requiring phosphorylation mediated by cGMP Natriuretic peptides alter blood pressure through a range of mechanisms which include contraction of plasma volume, inhibition of renin and aldosterone secretion, and a direct vasodilator effect. Interaction between natriuretic peptides and the RAAS may also occur in some blood vessels. In isolated vascular preparations, ANF shows a pronounced antagonism of angiotensin II induced vasoconstriction in large conduit arteries such as preparations of isolated aorta.29 In contrast, peripheral vessels (cerebral and mesenteric vessels in the rat and glomerular arterioles in the rabbit) preconstricted with noradrenaline or angiotensin II are insensitive to ANFs. Early human studies do not suggest preferential antagonism by natriuretic peptides of the net pressor effects of angiotensin II over that of noradrenaline. ANF and angiotensin II both constrict renal efferent arterioles,30 suggesting a common mechanism whereby both peptides preserve intraglomerular pressure and filtration.
Natriuretic peptides and angiotensin II may exert counterbalancing effects upon vascular cell growth and hypertrophy. Angiotensin II is a promoter of vascular smooth muscle cell growth.31 ANF inhibits vascular smooth muscle cell proliferation32 and attenuates the action of angiotensin II on vascular hypertrophy33 independently of its induction of proto-oncogenes. Natriuretic peptides antagonise growth factor dependent DNA synthesis and cell proliferation of cardiac fibroblasts.34 These counterpoised effects of natriuretic peptides and angiotensin II on cardiovascular cell growth suggest that the combination of ACE inhibition with natriuretic peptide enhancement (for example, with neutral endopeptidase inhibition) may oppose vascular and cardiac hypertrophy in human cardiovascular disease.
Angiotensin II and natriuretic peptide interactions may influence cardiac conduction and rhythm. Angiotensin II has a direct toxic effect upon cardiac cells,35 and in the setting of cardiac ischaemia angiotensin II may be proarrhythmic. Little is known of the effect of natriuretic peptide on cardiac conduction and rhythm. Crozier et al 36 infused exogenous ANF during cardiac electrophysiological studies in man. ANF induced falls in intraatrial conduction time, PR interval, right atrial effective refractory period, and ventriculoatrial refractory period. In the isolated perfused heart (rat), angiotensin II exacerbated ischaemia induced ventricular fibrillation, impaired cardiodynamics, and increased the release of creatine kinase. These effects were abolished by ANF,37 which increased myocardial glycogen, ATP, and creatine phosphate, and decreased lactate levels. Angiotensin II induced deterioration in these metabolic variables. Hence, natriuretic peptides may offer protection against the metabolic and arrhyth- Natriuretic peptide infusions in human hypertension Early studies confirmed the natriuretic and hypotensive effects of ANF in human hypertension, but the large doses of ANF used in these studies induced compensatory reflex responses that tended to disguise the primary inhibitory effect of ANF on the RAAS which became apparent in later work. In essential hypertension, ANF doses of 1 and 2 pmol/kg/min increased plasma ANF to concentrations which remained within the range observed in hypertension. Despite a clear, dose related fall in arterial pressure and a significant natriuresis, RAAS activity was not stimulated.6' ANF infusions (0 75 pmol/kg/ min) inducing a shift in plasma peptide concentrations, entirely within the normal resting range, produced a natriuresis together with consistent suppression of plasma renin activity and aldosterone to less than 50% of time matched placebo values.62
Recently Ferri et a!63 have compared the effects of ANF infused into low renin and normal renin essential hypertensives. Basal plasma ANF was higher in low renin than in normal renin hypertensives. ANF (0 7 pmol/ kg/min for 3 h) induced a more rapid and pronounced decrement in the plasma aldosterone of low renin patients.
With respect to secondary hypertension, there are at least four reports of ANF given in primary aldosteronism55 at doses ranging 1 6 to 32 pmollkg/min. Blood pressure lowering and natriuretic effects were substantial and similar to those observed in essential hypertension. Unsurprisingly, plasma aldosterone levels were not altered by ANF. Hirata et a!64 infused ANF (8 pmollkg/min for 40 min) into renal parenchymal hypertensive, renovascular hypertensive, and normotensive control subjects. Blood pressure (-5%) and plasma aldosterone (-40%) decreased by a similar proportion in the three groups. Interestingly, plasma renin activity was not significantly affected in any group.
Overall, the inhibitory effects of natriuretic peptides on the RAAS are observed in both primary and secondary human hypertension, but may be modified by baseline RAAS activity.
Human BNP (2 pmol/kg/min) infused intravenously in controlled studies of untreated patients with essential hypertension increased plasma BNP to values (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) pmol/l) similar to those previously observed in other patients suffering from mild heart failure. Plasma aldosterone was significantly suppressed to 50% of placebo values, in association with the 2-5-fold increase in sodium excretion.65 Plasma renin activity was also inhibited. A later, similar study from Lazzeri et al66 induced a comparable increase in plasma BNP concentrations in association with a similar increase in sodium excretion and a trend towards suppression of plasma renin activity (-30%) which did reach significance. This may be because the number of sampling points (only two per study phase) was limited.
Inhibition of neutral endopeptidase 3*4*24*11 in hypertension Single doses or limited doses of neutral endopeptidase inhibitors have produced an increase in plasma ANF and BNP together with natriuresis, increases in plasma and urine cGMP, and suppression of the RAAS. These doses had little effect on blood pressure. 47 In contrast, chronic dosing with neutral endopeptidase inhibitors produces transient natriuresis, sustained elevation of cGMP, and a significant fall in arterial pressure in association with a delayed activation of the RAAS.47 67 68 Heart failure Plasma natriuretic peptide levels are increased in heart failure in proportion to the severity of cardiac dysfunction.69 Positive correlations exist between circulating ANF and BNP levels and cardiac filling pressures, while natriuretic peptide concentrations are inversely related to indices of left ventricular function. In cardiac failure, the normal inverse relation between plasma natriuretic peptide concentrations and RAAS activity is replaced with a positive correlation,70 presumably reflecting simultaneous stimulation of both natriuretic peptide (secondary to cardiac chamber distension) and renin release (in response to decreased renal perfusion). The latter effect probably overcomes the inhibitory action of raised circulating natriuretic peptide on renin release.
In the absence of a specific antagonist to natriuretic peptides, we cannot conclusively define their place in the pathophysiology of heart failure in man. Nevertheless, data are available from elegant animal experiments. Lee et In human heart failure, ANF consistently induces falls in cardiac preload and afterload, with transient increases in cardiac output and little change in heart rate. 69 The inhibitory effects of ANF on the RAAS are attenuated in heart failure. However, the absence of change in plasma levels of renin, angiotensin II, and aldosterone, despite haemodynamic effects, presumably indicates some persisting inhibitory effect of ANF on the RAAS.69
In the only full report available73 on human heart failure (New York Heart Association classes II-IV), BNP given at a high dose (33 pmol/kg/min) reduced left ventricular filling pressure and systemic vascular resistance while increasing cardiac output. In this study, BNP had no effect on heart rate or arterial pressure. Plasma aldosterone was suppressed while plasma renin activity was unchanged. In striking contrast to the attenuated natriuretic response to ANF usually observed in heart failure, these researchers reported an enhanced natriuretic response to BNP in comparison to that observed in normal controls. These findings require confirmation.
Endopeptidase inhibition in single and chronic dose studies has shown a beneficial effect in human heart failure, with reduction in left ventricular pressures and systemic arterial pressure and preservation of cardiac output in association with inhibition of renin activity.7476
Combined inhibition of ACE and neutral endopeptidase ACE inhibitors are an established treatment in hypertension and heart failure. ACE inhibition has the greatest haemodynamic effect when baseline activity of the RAAS is increased. As yet, neutral endopeptidase inhibition has no defined therapeutic application, although preliminary data suggest beneficial effects in hypertension and heart failure. However, efficacy may be curtailed by secondary activation of the RAAS. Hence combining these two modes of enzyme inhibition may augment the beneficial effects of either approach alone.
Pham et aF77 reported that in three rat models of hypertension neutral endopeptidase inhibition consistently enhanced natriuresis and levels of cGMP, ANF, and bradykinin. Blood pressure fell only in DOC-Na rats and was not altered in either SHR or renovascular hypertensive (two kidney, one clip) rats. ACE inhibition alone reduced blood pressure effectively in both SHR and renovascular animals, but not in the DOC-Na model. The two inhibitors combined augmented the diuresis and natriuresis observed in DOC-Na and SHR models and the fall in blood pressure in the SHR.
Glucoprilat and alatrioprilat (which have combined enzyme inhibitory activity) given in low dose to rodents prevented hypertension secondary to infused angiotensin I and enhanced (a) 
